Page 10«..9101112..2030..»

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Link:
Obseva Announces Appointment of Stephanie Brown to its Board of Directors

To Read More: Obseva Announces Appointment of Stephanie Brown to its Board of Directors
categoriaGlobal News Feed commentoComments Off on Obseva Announces Appointment of Stephanie Brown to its Board of Directors | dataNovember 22nd, 2021
Read All

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

By Dr. Matthew Watson

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Read more here:
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

To Read More: Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
categoriaGlobal News Feed commentoComments Off on Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix | dataNovember 22nd, 2021
Read All

Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen…

By daniellenierenberg

This article was originally published here

Sci Rep. 2021 Nov 5;11(1):21722. doi: 10.1038/s41598-021-01071-2.

ABSTRACT

Spinal cord regeneration is limited due to various obstacles and complex pathophysiological events after injury. Combination therapy is one approach that recently garnered attention for spinal cord injury (SCI) recovery. A composite of three-dimensional (3D) collagen hydrogel containing epothilone B (EpoB)-loaded polycaprolactone (PCL) microspheres (2.5 ng/mg, 10 ng/mg, and 40 ng/mg EpoB/PCL) were fabricated and optimized to improve motor neuron (MN) differentiation efficacy of human endometrial stem cells (hEnSCs). The microspheres were characterized using liquid chromatography-mass/mass spectrometry (LC-mas/mas) to assess the drug release and scanning electron microscope (SEM) for morphological assessment. hEnSCs were isolated, then characterized by flow cytometry, and seeded on the optimized 3D composite. Based on cell morphology and proliferation, cross-linked collagen hydrogels with and without 2.5 ng/mg EpoB loaded PCL microspheres were selected as the optimized formulations to compare the effect of EpoB release on MN differentiation. After differentiation, the expression of MN markers was estimated by real-time PCR and immunofluorescence (IF). The collagen hydrogel containing the EpoB group had the highest HB9 and ISL-1 expression and the longest neurite elongation. Providing a 3D permissive environment with EpoB, significantly improves MN-like cell differentiation and maturation of hEnSCs and is a promising approach to replace lost neurons after SCI.

PMID:34741076 | DOI:10.1038/s41598-021-01071-2

Read this article:
Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen...

To Read More: Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen…
categoriaSpinal Cord Stem Cells commentoComments Off on Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen… | dataNovember 8th, 2021
Read All

Stem Cell & Regenerative Medicine Center University of …

By daniellenierenberg

UW Health treats first patient in U.S. with investigational cell therapy for heart disease

Appleton resident Donald Krause became the first patient in the country last week to undergo an investigational cell therapy for a debilitating heart condition called chronic myocardial ischemia (CMI). Krause was treated by Amish Raval, MD, an interventional cardiologist at UW Health, supported by Peiman Hematti, MD, a bone marrow transplantation hematologist at the UW School of Medicine and Public Health.

October 29, 2021SMPH News

Center members Dr. Anita Bhattacharyy and Dr. Su-Chun Zhang, in collaboration with Waisman and the University of Washington-Seattle and Seattle Childrens Hospital, have been awarded an $11 million Transformative Research grant from the National Institutes of Health to create a new approach using stem cells that may reveal how brain development in individuals with Down syndrome differs from typically developing individuals, identify features that will help understand their intellectual disability, and find potential targets for therapy. They will also address questions that remain unanswered about brain development overall.

October 7th, 2021UW News

The U.S. Food and Drug Administration on Tuesday approved StrataGraft, a topical treatment for severe burns made from skin tissue, providing a boost for Madison-based firm Stratatech. Stratatech was founded in 2000 by SCRMC member Lynn Allen-Hoffman, the first female University of Wisconsin-Madison faculty member to start a biotech company.

June 16, 2021The Cap Times

The Food and Drug Administration-approved trial will use a form of transplant that replaces a patients bone marrow with alpha-beta T-cell depleted peripheral blood stem cells from closely matched unrelated donors or family members.

May 27, 2021

Over the past two decades, stem cell research at UW-Madison has grown from involving a handful of scientists to nearly 100 from more than 30 schools, colleges and departments.

May 25, 2021Quarterly Magazine, Vol. 23, No. 1

Nine University of WisconsinMadison postdoctoral researchers have been recognized with the inaugural Postdoc Excellence Awards for their teaching, service and mentoring. Daniel Z. Radecki (Comparative Biosciences) received one of these awards.

The defining feature of Dans work with the (UWMadison Postdoctoral Association) and others is his commitment to bettering the lives of all postdocs. He envisions how each event and initiative can best impact the individual, through the lenses of diversity and inclusion, immigration status, postdocs personal lives (e.g. childcare considerations), department/discipline, and more.

Congratulations, Daniel!

April 29, 2021

Researchers at UWMadison have made new photoreceptors from human pluripotent stem cells. However, it remains challenging to precisely deliver those photoreceptors within the diseased or damaged eye so that they can form appropriate connections, says David Gamm, director of the McPherson Eye Research Institute and professor of ophthalmology and visual sciences at the UW School of Medicine and Public Health.

While it was a breakthrough to be able to make the spare parts these photoreceptors its still necessary to get them to the right spot so they can effectively reconstruct the retina, he says. So, we started thinking, How can we deliver these cells in a more intelligent way? Thats when we reached out to our world-class engineers at UWMadison.

Research from the University of WisconsinMadison finds that a new therapeutic approach for heart failure could help restore cardiac function by regenerating heart muscle. In a study recently published in the journal Circulation, the UW team describes its success in improving, in a mouse model, the function of heart muscle by temporarily blocking a key metabolic enzyme after a heart attack. This simple intervention, the researchers say, could ultimately help people regain cardiac function. Our goal was to gain new understanding of how the heart can heal itself following injury at the molecular and cellular level and see if there was a way to restore cardiac function to an earlier state, says UWMadisons Ahmed Mahmoud, professor of cell and regenerative biology in the School of Medicine and Public Health.

Learn more about the research here.April 15, 2021

Grafting neurons grown from monkeys own cells into their brains relieved the debilitating movement and depression symptoms associated with Parkinsons disease, researchers at the University of WisconsinMadison reported today. In a study published in the journal Nature Medicine the UW team describes its success with neurons made from cells from the monkeys own bodies after reprogramming to induced pluripotent stem cells. UWMadison neuroscientist Su-Chun Zhang, whose Waisman Center lab grew the brain cells, said this approach avoided complications with the primates immune systems and takes an important step toward a treatment for millions of human Parkinsons patients. Learn more about their work here.March 1, 2021

The project, led by David Gamm, MD, PhD, director of the McPherson Eye Research Institute and professor of ophthalmology and visual sciences at the UW School of Medicine and Public Health, will develop a transplantable patch to restore vision to members of the armed forces who have been injured by blasts or lasers.December 11, 2020

This week, the NIH Office of Research Infrastructure Programs highlights Dr. Marina Emborg, her WNPRC lab team and their UWMadison colleagues advances in detecting heart disease in Parkinsons and evaluating new therapies that specifically target nerve disease within the human heart.December 2020

Its been 25 years since University of WisconsinMadison scientist James Thomson became the first in the world to successfully isolate and culture primate embryonic stem cells. He accomplished this breakthrough first with nonhuman primates at the Wisconsin National Primate Research Center in 1995, using rhesus monkey cells, then in 1996 with marmoset cells. Thomson then published his world-changing breakthrough on human embryonic stem cell derivation in Science on Nov. 6, 1998.November 6, 2020

EEMs and exosomes each have attractive characteristics as therapeutics, Dr. Hematti, UW-Madisons Department of Medicine, noted. As a cell therapy, EEMs will not proliferate or differentiate to undesirable cell types, which remains a concern for many stem cell therapies. Moreover, EEMs could be generated from a patients own monocytes using off-the-shelf exosomes, resulting in a faster and more facile process compared to autologous MSCs. Alternatively, exosome therapy could be a cell free, shelf-stable therapeutic to deliver biologically active components. Altogether, we believe our studies results support the use of EEMs and/or exosomes to improve ligament healing by modulating inflammation and tissue remodeling, Dr. Vanderby concluded.November 3, 2020

View more news posts

View news archives

Visit link:
Stem Cell & Regenerative Medicine Center University of ...

To Read More: Stem Cell & Regenerative Medicine Center University of …
categoriaCardiac Stem Cells commentoComments Off on Stem Cell & Regenerative Medicine Center University of … | dataNovember 8th, 2021
Read All

Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant…

By Dr. Matthew Watson

BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation.

Excerpt from:
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant...

To Read More: Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant…
categoriaGlobal News Feed commentoComments Off on Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant… | dataNovember 8th, 2021
Read All

Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

By Dr. Matthew Watson

REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA® (pegfilgrastim-cbqv).

Read the original here:
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

To Read More: Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
categoriaGlobal News Feed commentoComments Off on Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 | dataNovember 8th, 2021
Read All

Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

By Dr. Matthew Watson

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.

The rest is here:
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

To Read More: Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
categoriaGlobal News Feed commentoComments Off on Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial | dataNovember 8th, 2021
Read All

Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

By Dr. Matthew Watson

Bagsværd, Denmark, 5 November 2021 – Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period. The STEP 5 trial investigated Wegovy™ vs. placebo, both used with a reduced calorie meal plan and increased physical activity for the treatment of obesity (BMI ?30 kg/m2) or overweight (BMI ?27 kg/ m2) in 304 adults with at least one weight-related comorbidity for 104 weeks (two years).1

View original post here:
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

To Read More: Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
categoriaGlobal News Feed commentoComments Off on Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity | dataNovember 8th, 2021
Read All

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

By Dr. Matthew Watson

Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study

Read more:
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

To Read More: Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
categoriaGlobal News Feed commentoComments Off on Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes | dataNovember 8th, 2021
Read All

I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.

By Dr. Matthew Watson

MONTREAL, Nov. 05, 2021 (GLOBE NEWSWIRE) -- I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market. Their uniquely formulated line of ocular surface disorder products gives dry eye patients the long-lasting relief they have been searching for. I-MED Pharma USA will sell directly to eye care professionals throughout the United States, offering a broad range product portfolio which includes I-DROP® artificial tears, I-LID ’N LASH® ocular hygiene cleansers, I-DEFENCE® night-time dry eye ointment, I-VU® OMEGA-3 nutritional supplements, I-RELIEF™ therapeutic mask, and the E>Eye IRPL® device specifically designed to treat evaporative dry eye due to meibomian gland dysfunction.

More:
I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.

To Read More: I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.
categoriaGlobal News Feed commentoComments Off on I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A. | dataNovember 8th, 2021
Read All

PAOG Announces Plans To Add New Pharmaceutical Product Developments

By Dr. Matthew Watson

Sandusky, OH, Nov. 05, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Read this article:
PAOG Announces Plans To Add New Pharmaceutical Product Developments

To Read More: PAOG Announces Plans To Add New Pharmaceutical Product Developments
categoriaGlobal News Feed commentoComments Off on PAOG Announces Plans To Add New Pharmaceutical Product Developments | dataNovember 8th, 2021
Read All

MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market

By Dr. Matthew Watson

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”.

Read this article:
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market

To Read More: MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
categoriaGlobal News Feed commentoComments Off on MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market | dataNovember 8th, 2021
Read All

Bavarian Nordic to Host Third Quarter 2021 Results Conference Call

By Dr. Matthew Watson

COPENHAGEN, Denmark – November 5, 2021 - Bavarian Nordic A/S (OMX:  BAVA) will announce its 2021 third quarter results on Friday, November 12, 2021.

View original post here:
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call

To Read More: Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
categoriaGlobal News Feed commentoComments Off on Bavarian Nordic to Host Third Quarter 2021 Results Conference Call | dataNovember 8th, 2021
Read All

Tauriga Sciences, Inc. Reports Continued Strength and Accelerating Growth in its Highest Margin E-Commerce Business Segment

By Dr. Matthew Watson

NEW YORK, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today reported continued strength and accelerating growth in its highest margin E-Commerce business segment (“E-Comm”).  The Company generated strong monthly E-Comm sales for the recently completed month of October 2021.  As of today’s date, November 5, 2021, the Company is firmly on track to generate record quarterly E-Comm sales – for its current operating quarter (October 1st– December 31st 2021).

Link:
Tauriga Sciences, Inc. Reports Continued Strength and Accelerating Growth in its Highest Margin E-Commerce Business Segment

To Read More: Tauriga Sciences, Inc. Reports Continued Strength and Accelerating Growth in its Highest Margin E-Commerce Business Segment
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences, Inc. Reports Continued Strength and Accelerating Growth in its Highest Margin E-Commerce Business Segment | dataNovember 8th, 2021
Read All

Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021

By Dr. Matthew Watson

Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021.

The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021

To Read More: Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021
categoriaGlobal News Feed commentoComments Off on Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021 | dataNovember 8th, 2021
Read All

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

By Dr. Matthew Watson

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.

Originally posted here:
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

To Read More: CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
categoriaGlobal News Feed commentoComments Off on CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10 | dataNovember 8th, 2021
Read All

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

By Dr. Matthew Watson

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

Read more:
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

To Read More: TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021
categoriaGlobal News Feed commentoComments Off on TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021 | dataNovember 8th, 2021
Read All

MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market

By Dr. Matthew Watson

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ. The shares closed above the offering price at $9.99.

Go here to read the rest:
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market

To Read More: MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
categoriaGlobal News Feed commentoComments Off on MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market | dataNovember 8th, 2021
Read All

atai Life Sciences to Participate in Upcoming November Investor Conferences

By Dr. Matthew Watson

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:

View post:
atai Life Sciences to Participate in Upcoming November Investor Conferences

To Read More: atai Life Sciences to Participate in Upcoming November Investor Conferences
categoriaGlobal News Feed commentoComments Off on atai Life Sciences to Participate in Upcoming November Investor Conferences | dataNovember 8th, 2021
Read All

Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

By Dr. Matthew Watson

Bagsværd, Denmark, 5 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Follow this link:
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

To Read More: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
categoriaGlobal News Feed commentoComments Off on Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021 | dataNovember 8th, 2021
Read All

Page 10«..9101112..2030..»